This archive contains the following articles listed by volume, issue and page number:
 |
|
|
CANCER AND AIDS RELATED ARTICLES |
Title (Click for Details) |
Vol/Issue |
Page |
Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel |
Vol. 24 No. 2 |
168 |
Calculations |
Vol. 24 No. 1 |
52 |
Compatibility of Melphalan in Iodinated Contrast Media |
Vol. 24 No. 1 |
83 |
Compounded Cyclophosphamide and Piroxicam for the Treatment of a Canine Peripheral Nerve Sheath Tumor: A Case Report |
Vol. 23 No. 5 |
358 |
Sorafenib Capsules for Pediatric Use |
Vol. 23 No. 5 |
411 |
Methotrexate 2-mg/mL Oral Solution |
Vol. 23 No. 3 |
235 |
Lidocaine Hydrochloride, Diphenhydramine Hydrochloride, Aluminum Hydroxide–Magnesium Hydrochloride–Simethicone Mouthwashes |
Vol. 23 No. 1 |
54 |
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications |
Vol. 22 No. 6 |
446 |
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions |
Vol. 22 No. 6 |
496 |
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags |
Vol. 22 No. 5 |
417 |
Calculations |
Vol. 22 No. 4 |
314 |
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension |
Vol. 22 No. 4 |
318 |
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags |
Vol. 22 No. 4 |
345 |
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture |
Vol. 22 No. 3 |
237 |
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture |
Vol. 22 No. 2 |
151 |
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension |
Vol. 22 No. 1 |
51 |
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension |
Vol. 22 No. 1 |
58 |
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing |
Vol. 22 No. 1 |
60 |
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection |
Vol. 22 No. 1 |
76 |
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride |
Vol. 22 No. 1 |
86 |
Etoposide 20-mg/mL Injection |
Vol. 21 No. 5 |
410 |
Tacrolimus 0.3-mg/mL Ophthalmic Solution |
Vol. 21 No. 5 |
416 |
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia |
Vol. 21 No. 4 |
347 |
Azathioprine 10-mg/mL Oral Suspension |
Vol. 21 No. 2 |
146 |
Calculations |
Vol. 21 No. 1 |
58 |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate |
Vol. 21 No. 1 |
66 |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride |
Vol. 21 No. 1 |
76 |
Erlotinib 10-mg/mL Oral Suspension |
Vol. 20 No. 6 |
508 |
Imatinib 40-mg/mL Oral Suspension |
Vol. 20 No. 6 |
510 |
Lapatinib Ditosylate 50-mg/mL Oral Suspension |
Vol. 20 No. 6 |
511 |
Calculations |
Vol. 20 No. 5 |
405 |
Tretinoin 10-mg Oral Capsules |
Vol. 20 No. 4 |
327 |
Carboplatin 50-mg/mL Injection |
Vol. 20 No. 3 |
226 |
Aprepitant 80-mg Capsules |
Vol. 20 No. 1 |
48 |
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date |
Vol. 20 No. 1 |
81 |
Calculations |
Vol. 19 No. 6 |
502 |
Cytarabine 50-mg/mL Injection |
Vol. 19 No. 4 |
328 |
Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg |
Vol. 19 No. 4 |
333 |
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes |
Vol. 19 No. 4 |
344 |
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials |
Vol. 19 No. 3 |
261 |
Cisplatin 1-mg/mL Injection |
Vol. 19 No. 1 |
62 |
Daunorubicin 5-mg/mL Injection |
Vol. 19 No. 1 |
63 |
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions |
Vol. 19 No. 1 |
73 |
Leucovorin 10-mg/mL Injection |
Vol. 18 No. 6 |
497 |
High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products |
Vol. 18 No. 6 |
520 |
Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy |
Vol. 18 No. 5 |
358 |
Denileukin Diftitox 150-mcg/mL Injection |
Vol. 18 No. 4 |
328 |
Methotrexate 2.5-mg Capsules |
Vol. 18 No. 3 |
238 |
Tamoxifen 10-mg or 20-mg Capsules |
Vol. 18 No. 3 |
240 |
Fludarabine Phosphate 25-mg/mL Injection |
Vol. 18 No. 2 |
143 |
Secretin 4 mcg/mL Injection |
Vol. 18 No. 2 |
148 |
Lomustine 100-mg Capsules |
Vol. 18 No. 1 |
63 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 |
Vol. 17 No. 6 |
446 |
Metyrosine 250-mg Capsules |
Vol. 17 No. 6 |
506 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1 |
Vol. 17 No. 5 |
388 |
Fluorouracil 50-mg/mL Injection |
Vol. 17 No. 5 |
417 |
Mesna 100-mg/mL Injection |
Vol. 17 No. 5 |
420 |
Methotrexate 25-mg/mL Injection |
Vol. 17 No. 5 |
421 |
Dacarbazine 200-mg/mL Injection |
Vol. 17 No. 4 |
330 |
Mercaptopurine 75-mg Capsules |
Vol. 17 No. 3 |
234 |
PostScription: The Pharmacist's Role in the Treatment of Cancer: A Personal Plea and Testimonial |
Vol. 17 No. 3 |
262 |
Dexrazoxane 1-mg/mL Injection |
Vol. 17 No. 2 |
149 |
Paclitaxel 6-mg/mL Injection |
Vol. 17 No. 2 |
151 |
Thiotepa 15-mg/mL Injection |
Vol. 17 No. 2 |
152 |
Granisetron 1-mg/mL Injection |
Vol. 17 No. 1 |
66 |
Octreotide 50-mcg/mL Injection |
Vol. 17 No. 1 |
72 |
Testosterone Cypionate 100-mg/mL Injection |
Vol. 17 No. 1 |
73 |
Calculations |
Vol. 16 No. 6 |
498 |
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time |
Vol. 16 No. 5 |
431 |
Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization |
Vol. 16 No. 5 |
434 |
Ondansetron Hydrochloride 2-mg/mL Injection |
Vol. 16 No. 4 |
339 |
Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum |
Vol. 16 No. 2 |
117 |
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration |
Vol. 16 No. 1 |
82 |
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management |
Vol. 16 No. 1 |
22 |
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers |
Vol. 15 No. 6 |
458 |
Thioguanine 20-mg/mL Oral Suspension |
Vol. 15 No. 6 |
506 |
Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion |
Vol. 15 No. 6 |
504 |
Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags |
Vol. 15 No. 6 |
515 |
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension |
Vol. 15 No. 5 |
419 |
Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions |
Vol. 15 No. 5 |
428 |
Methylprednisolone 4-mg/mL Oral Suspension |
Vol. 15 No. 4 |
340 |
Panitumumab 2.5-mg/mL in 0.9% Sodium Chloride Injection |
Vol. 14 No. 5 |
428 |
Potential Treatments for Radiation Dermatitis |
Vol. 14 No. 3 |
210 |
Cyclophosphamide 10-mg/mL Oral Suspension |
Vol. 14 No. 3 |
245 |
Sunitinib 10-mg/mL Oral Suspension |
Vol. 14 No. 3 |
248 |
Hormonal Influences in Prostate Cancer: An Update of a Complex Subject |
Vol. 14 No. 2 |
100 |
Developing a Tretinoin Oral Liquid for Patients Who Cannot Take Capsules |
Vol. 14 No. 2 |
118 |
Mechlorethamine Hydrochloride 0.02% Topical |
Vol. 13 No. 5 |
434 |
Myristyl Nicotinate 5% Topical Gel |
Vol. 13 No. 5 |
435 |
Aprepitant 20-mg/mL Oral Liquid |
Vol. 13 No. 2 |
153 |
Doxorubicin Hydrochloride 1-mg/mL in Sodium Chloride Solution Intravesical Instillation |
Vol. 13 No. 2 |
155 |
Ionic Hydration Solution for Anti-Cancer Therapy |
Vol. 13 No. 2 |
156 |
Compounding for Cancer in Companion Animals |
Vol. 13 No. 1 |
42 |
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration |
Vol. 12 No. 5 |
460 |
Compounding Challenges for Immunocompromised Patients |
Vol. 12 No. 6 |
482 |
Tretinoin and Dexpanthenol Gel |
Vol. 12 No. 4 |
361 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration |
Vol. 12 No. 4 |
368 |
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients |
Vol. 12 No. 1 |
16 |
Hospice and Compounding Pharmacy: Once Inseperable |
Vol. 12 No. 1 |
28 |
Calculations: Compounding for Cancer Patients |
Vol. 12 No. 1 |
62 |
Temozolomide 10-mg/mL Oral Liquid |
Vol. 11 No. 4 |
336 |
Levorphanol for Excruciating Pain from Oral Cancer: A Case Report |
Vol. 11 No. 3 |
212 |
Busulfan 2-mg/mL Oral Liquid |
Vol. 11 No. 2 |
155 |
Ondansetron Hydrochloride 0.8mg/mL Oral Liquid |
Vol. 11 No. 2 |
158 |
Phenoxybenzamine Hydrochloride 2-mg/mL Oral Liquid |
Vol. 11 No. 2 |
160 |
Principles of Pediatric Palliative Care and Pain Control |
Vol. 11 No. 1 |
10 |
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration |
Vol. 11 No. 1 |
82 |
Cyclophosphamide 2-mg/mL Oral Liquid |
Vol. 10 No. 6 |
454 |
Dermatological Effects from Years in the Sun: Compounding Opportunities |
Vol. 10 No. 5 |
336 |
Hydroxyurea 100 mg/mL |
Vol. 10 No. 5 |
384 |
Indinavir 10-mg/mL Oral Liquid |
Vol. 10 No. 5 |
385 |
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions |
Vol. 10 No. 5 |
396 |
Rifabutin 20-mg/mL Oral Liquid |
Vol. 10 No. 4 |
305 |
Granisetron 0.05-mg/mL Oral Suspension |
Vol. 10 No. 3 |
222 |
Mesna 20-mg/mL Syrup |
Vol. 10 No. 3 |
224 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration |
Vol. 10 No. 3 |
234 |
Chlorambucil 2-mg/mL Oral Liquid |
Vol. 10 No. 1 |
59 |
Efavirenz 20-mg/mL Oral Liquid, Anhydrous |
Vol. 10 No. 1 |
62 |
Mercaptopurine 50-mg/mL Oral Liquid |
Vol. 10 No. 1 |
64 |
Thioguanine 40-mg/mL Oral Liquid |
Vol. 10 No. 1 |
68 |
Dolasetron 10-mg/mL Oral Liquid |
Vol. 9 No. 6 |
475 |
Brompton's Mixture |
Vol. 9 No. 4 |
312 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration |
Vol. 9 No. 4 |
320 |
Compounding Antiangiogenic Cancer Therapy for Animals |
Vol. 9 No. 3 |
195 |
Piroxicam 2-mg/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
234 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration |
Vol. 9 No. 3 |
235 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration |
Vol. 9 No. 3 |
238 |
Book and Literature Reviews |
Vol. 8 No. 5 |
324 |
Acyclovir 5% and Chlorhexidine Diacetate 0.2% Topical Gel |
Vol. 8 No. 5 |
383 |
Book and Literature Reviews |
Vol. 8 No. 4 |
244 |
Diphenhydramine HCl 0.1%, Lidocaine HCl 1%, Misoprostol 0.0024% and Triamcinolone Acetonide 0.12% Oral Rinse |
Vol. 8 No. 4 |
296 |
Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
218 |
Stomatitis Mouthwash |
Vol. 8 No. 2 |
140 |
Tacrolimus 0.5-mg/mL Oral Liquid |
Vol. 8 No. 2 |
141 |
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder |
Vol. 7 No. 5 |
386 |
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) |
Vol. 7 No. 3 |
183 |
The Hormonal Link to Breast Cancer: The Estrogen Matrix |
Vol. 6 No. 4 |
250 |
Sterilization of Talc for Use in Pleurodesis |
Vol. 6 No. 2 |
140 |
Antineoplastic Agents |
Vol. 5 No. 4 |
268 |
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes |
Vol. 5 No. 4 |
320 |
Mitomycin 0.02% Ophthalmic Solution |
Vol. 5 No. 3 |
209 |
Promethazine HCl 50-mg/mL in PLO Gel |
Vol. 5 No. 1 |
51 |
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome |
Vol. 4 No. 5 |
334 |
Hospice and the Role of the Compounding Pharmacist |
Vol. 4 No. 4 |
246 |
Nausea and Vomiting in Hospice Patients |
Vol. 4 No. 4 |
250 |
Ketamine for Pain in Hospice Patients |
Vol. 4 No. 4 |
253 |
Custom-Making Medications for the Hospice Patient |
Vol. 4 No. 4 |
255 |
Surviving Cancer - How the Compounding Pharmacist Can Help |
Vol. 4 No. 4 |
257 |
Providing Positive Outcomes through Compounding for Animal Cancer Patients |
Vol. 4 No. 4 |
264 |
Dacarbazine 8-mg/mL, Doxorubicin HCl 0.8-mg/mL and Ondansetron 0.64-mg/mL injection |
Vol. 4 No. 4 |
296 |
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO |
Vol. 4 No. 4 |
297 |
Doxorubicin HCl 0.4-mg/mL, Ondansetron HCl 0.48-mg/mL and Vincristine Sulfate 14-mcg/mL Injection |
Vol. 4 No. 4 |
298 |
Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations |
Vol. 4 No. 4 |
302 |
Ondansetron HCl 8-mg/mL in PLO |
Vol. 4 No. 4 |
305 |
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution |
Vol. 4 No. 4 |
320 |
Tamoxifen Citrate - A Potential Therapy for the Treatment of Keloids |
Vol. 3 No. 5 |
380 |
Tamoxifen Citrate Cream 0.1% |
Vol. 3 No. 5 |
381 |
Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration |
Vol. 3 No. 3 |
241 |
Oral Ulceration Mouthwash |
Vol. 3 No. 1 |
10 |
Five-Day Stability of Vinorelbine in 5% Dextrose Injection and in 0.9% Sodium Chloride Injection at Room Temperature |
Vol. 3 No. 1 |
67 |
Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists |
Vol. 2 No. 6 |
414 |
Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump |
Vol. 2 No. 5 |
382 |
Fluorouracil 5% Topical Stick |
Vol. 2 No. 4 |
300 |
Paclitaxel Compatibility with IV Express Filter Unit |
Vol. 2 No. 3 |
243 |
Estrogen and Breast Cancer: Is There a Link? |
Vol. 2 No. 1 |
21 |
Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane |
Vol. 2 No. 1 |
83 |
Stability of Mechlorethamine Hydrochloride 0.01% Ointment in Aquaphor® Base |
Vol. 2 No. 1 |
89 |
Compounding Pharmacists Play a Vital Role in AIDS Treatment |
Vol. 1 No. 6 |
386 |
Doxorubicin HCl-Vincristine Sulfate Injection |
Vol. 1 No. 5 |
324 |
Granisetron HCl-Dexamethasone Sodium Phosphate Injection |
Vol. 1 No. 5 |
326 |
Metoclopramide-Lorazepam-Mannitol-Prochlorperazine Antiemetic Injection |
Vol. 1 No. 5 |
328 |
Ondansetron HCl-Dexamethasone Sodium Phosphate Injection |
Vol. 1 No. 5 |
332 |
Ondansetron HCl-Doxorubicin HCl-Dacarbazine Injection |
Vol. 1 No. 5 |
333 |
Ondansetron HCl-Doxorubicin Sulfate-Vincristine Sulfate Injection (2 concentrations) |
Vol. 1 No. 5 |
334 |
Stability of Mitomycin Aqueous Solution When Stored in Tuberculin Syringes |
Vol. 1 No. 4 |
282 |
Antiemetic Injection for Cancer Chemotherapy |
Vol. 1 No. 3 |
175 |
Rectal and Stomal Administration of Analgesic Suppositories |
Vol. 1 No. 1 |
12 |
Aromatherapy and the Hospice Patient |
Vol. 1 No. 1 |
18 |
ABH Hard Troche |
Vol. 1 No. 1 |
26 |
ABH Soft Troche |
Vol. 1 No. 1 |
27 |
ABH Sugar Troche |
Vol. 1 No. 1 |
27 |
Antiemetic Suppositories of the Gralla Type |
Vol. 1 No. 1 |
28 |
Metoclophen Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Metoclophen-Modified Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Ondansetron HCl Suppositories |
Vol. 1 No. 1 |
34 |
Scopolamine Hydrobromide 0.4-mg/0.1-mL Nasal Solution |
Vol. 1 No. 1 |
37 |
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel |
Vol. 1 No. 1 |
38 |
Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion |
Vol. 1 No. 1 |
49 |
 |
|
|
HOSPICE/PALLIATIVE CARE RELATED ARTICLES |
Title (Click for Details) |
Vol/Issue |
Page |
Glycopyrrolate 0.2 mg/mL in Methylcellulose 1% and Syrup |
Vol. 24 No. 1 |
56 |
Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice |
Vol. 18 No. 3 |
190 |
Palliative Care and Compounding for Household Pets |
Vol. 16 No. 6 |
452 |
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report |
Vol. 16 No. 5 |
364 |
When Traditional Medicine Fails |
Vol. 14 No. 1 |
6 |
Compounding for Cancer in Companion Animals |
Vol. 13 No. 1 |
42 |
Topical Treatment of Neuropathic Pain |
Vol. 12 No. 3 |
182 |
Hospice and Compounding Pharmacy: Once Inseperable |
Vol. 12 No. 1 |
28 |
Principles of Pediatric Palliative Care and Pain Control |
Vol. 11 No. 1 |
10 |
Hospice Symptom Relief Kit: An Update |
Vol. 10 No. 4 |
288 |
Aseptic Compounding in New Zealand and the Use of Still Air Boxes |
Vol. 10 No. 4 |
293 |
Initial Selection of Antiemetics in End-of-Life Care: A Retrospective Analysis |
Vol. 10 No. 2 |
147 |
Hospice from a Compounding Pharmacist's Perspective |
Vol. 10 No. 2 |
89 |
ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient |
Vol. 10 No. 2 |
95 |
The Story of Hospice |
Vol. 10 No. 2 |
100 |
The Dying Process |
Vol. 10 No. 2 |
103 |
Current Topical Treatments in Wound Healing - Part 1 |
Vol. 8 No. 4 |
269 |
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel |
Vol. 8 No. 3 |
185 |
Indomethacin 50-mg Suppositories |
Vol. 7 No. 5 |
375 |
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) |
Vol. 7 No. 3 |
183 |
Hospice and the Role of the Compounding Pharmacist |
Vol. 4 No. 4 |
246 |
Nausea and Vomiting in Hospice Patients |
Vol. 4 No. 4 |
250 |
Ketamine for Pain in Hospice Patients |
Vol. 4 No. 4 |
253 |
Custom-Making Medications for the Hospice Patient |
Vol. 4 No. 4 |
255 |
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations |
Vol. 4 No. 4 |
289 |
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO |
Vol. 4 No. 4 |
297 |
Managing Pain in the Terminally Ill |
Vol. 2 No. 2 |
111 |
The Symptom Relief Kit for Hospice Patients |
Vol. 2 No. 2 |
116 |
Compounding Pharmacists Play a Vital Role in AIDS Treatment |
Vol. 1 No. 6 |
386 |
Hospice Care and the Pharmacist |
Vol. 1 No. 1 |
11 |
Rectal and Stomal Administration of Analgesic Suppositories |
Vol. 1 No. 1 |
12 |
Aromatherapy and the Hospice Patient |
Vol. 1 No. 1 |
18 |
Aromatherapy Mood Elevation No. 1 |
Vol. 1 No. 1 |
20 |
Aromatherapy Mood Elevation No. 2 |
Vol. 1 No. 1 |
21 |
ABH Hard Troche |
Vol. 1 No. 1 |
26 |
ABH Soft Troche |
Vol. 1 No. 1 |
27 |
ABH Sugar Troche |
Vol. 1 No. 1 |
27 |
Morphine Sulfate Slow-Release Suppositories |
Vol. 1 No. 1 |
32 |
Ondansetron HCl Suppositories |
Vol. 1 No. 1 |
34 |
Morphine Suppositories |
Vol. 1 No. 1 |
36 |